Teva Pharmaceutical Industries (TEVA) Non Operating Income (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Non Operating Income came in at -$224.0 million in Q2 2026, up 11.11% YoY from -$201.6 million in Q2 2025, and down 3.7% on a QoQ basis from -$216.0 million in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Non Operating Income (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Non Operating Income data on file, last reported at -$224.0 million in Q2 2026.
- Quarterly Non Operating Income rose 11.11% year-over-year to -$224.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$897.0 million (up 7.24% YoY) and the FY2025 annual result came in at -$934.0 million, up 4.79% from the prior year.
- Non Operating Income eased to -$224.0 million in Q2 2026, from -$216.0 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of -$211.0 million in Q2 2022 to a low of -$280.0 million in Q3 2023.
- A 5-year average of -$243.2 million and a median of -$247.0 million in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income rose 22.99% — and 2023, when it slipped 27.01%.
- Tracing TEVA's Non Operating Income over 5 years: stood at -$245.0 million in 2022, then fell by 1.63% to -$249.0 million in 2023, then increased by 12.45% to -$218.0 million in 2024, then fell by 0.92% to -$220.0 million in 2025, then dropped by 1.82% to -$224.0 million in 2026.
- The last three Non Operating Income figures came in at -$224.0 million (Q2 2026), -$216.0 million (Q1 2026), and -$220.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.71 Bn | 42.75 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.11 Bn | 39.45 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 31.62 Bn | 29.94 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.33 Bn | 19.67 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 12.10 Bn | 11.57 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.25 Bn | 7.60 Bn | 397.90 Mn | -20.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -224.00 Mn |
| Mar 31, 2026 | -216.00 Mn |
| Dec 31, 2025 | -220.00 Mn |
| Sep 30, 2025 | -237.00 Mn |
| Jun 30, 2025 | -252.00 Mn |
| Mar 31, 2025 | -225.00 Mn |
| Dec 31, 2024 | -218.00 Mn |
| Sep 30, 2024 | -272.00 Mn |
| Jun 30, 2024 | -241.00 Mn |
| Mar 31, 2024 | -250.00 Mn |
| Dec 31, 2023 | -249.00 Mn |
| Sep 30, 2023 | -280.00 Mn |
| Jun 30, 2023 | -268.00 Mn |
| Mar 31, 2023 | -260.00 Mn |
| Dec 31, 2022 | -245.00 Mn |
| Sep 30, 2022 | -252.00 Mn |
| Jun 30, 2022 | -211.00 Mn |
| Mar 31, 2022 | -258.00 Mn |
| Dec 31, 2021 | -253.00 Mn |
| Sep 30, 2021 | -241.00 Mn |